Brainstorm receives fda clearance to initiate phase 3b trial of nurown® for als

Investor call and webcast scheduled for today at 8:30 a.m. et new york , may 19, 2025 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the u.s. food and drug administration (fda) has cleared the company to initiate its phase 3b clinical trial of nurown® (autologous msc-ntf cells) for the treatment of amyotrophic lateral sclerosis (als).
BCLI Ratings Summary
BCLI Quant Ranking